← Back to Search

[18F]F-AraG PET Imaging for Lung Cancer

Phase 1

Waitlist Available

Led By Martin Pomper, M.D., Ph.D.

Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial will use a radioactive compound to detect changes in a patient's cancer immunotherapy response.

Who is the study for?

This trial is for adults with early-stage non-small cell lung cancer (NSCLC) who are fit enough to give consent and have a reasonable level of physical function. They should be planning to receive immunotherapy before surgery aimed at curing their cancer. Women able to have children must test negative for pregnancy.Check my eligibility

What is being tested?

[18F]F-AraG Injection is being tested as an imaging agent in patients with NSCLC undergoing PD-1/PD-L1-directed therapy. The goal is to see if it can detect changes in the immune system's response against tumor cells when treated with immunotherapy.See study design

What are the potential side effects?

Potential side effects from [18F]F-AraG are not detailed, but as a radioactive compound used for PET imaging, there may be exposure-related risks such as allergic reactions or radiation-associated hazards.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Correlation between [18F]F-AraG uptake and percent pathologic response as assessed by the Spearman correlation coefficient

Percent Change in uptake of [18F]F-AraG before and after one dose of anti-PD-L1

Percent pathologic response at the time of surgery

Trial Design

1Treatment groups

Experimental Treatment

Group I: [18F]F-AraGExperimental Treatment1 Intervention

A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Industry Sponsor

17 Previous Clinical Trials

307 Total Patients Enrolled

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor

557 Previous Clinical Trials

32,896 Total Patients Enrolled

Stand Up To CancerOTHER

51 Previous Clinical Trials

40,290 Total Patients Enrolled

Media Library

[18F]F-AraG Injection Clinical Trial Eligibility Overview. Trial Name: NCT04524195 — Phase 1

Non-Small Cell Lung Cancer Research Study Groups: [18F]F-AraG

Non-Small Cell Lung Cancer Clinical Trial 2023: [18F]F-AraG Injection Highlights & Side Effects. Trial Name: NCT04524195 — Phase 1

[18F]F-AraG Injection 2023 Treatment Timeline for Medical Study. Trial Name: NCT04524195 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are enrolled in this research?

"Affirmative. According to clinicaltrials.gov, this study—which was first posted on February 1st 2021—is presently recruiting participants. 20 people are needed between two distinct sites."

Answered by AI

Does [18F]F-AraG Injection pose any potential risks to those who receive it?

"Since this is the inaugural stage of clinical testing for [18F]F-AraG Injection, there is limited evidence to demonstrate its safety and efficacy, thus earning it a score of 1."

Answered by AI

Have the recruitments for this trial begun yet?

"Affirmative. Clinicaltrials.gov hosts information indicating that this clinical trial is actively recruiting participants, with 20 patients needed from 2 separate locations since the initial posting on February 1st 2021 and last update on December 14th 2021."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

2021. "PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04524195.